Our Blog | Quotient Sciences

Upcoming webinar

Advancing the Pharmaceutical Development of Orphan Drugs for Rare Diseases

Orphan Drug Development

Orphan Drug Development For Rare Diseases

5 / 18 posts displayed

Translational Pharmaceutics

Tuft’s Center for the Study of Drug Development partners with Quotient Sciences for study on Translational Pharmaceutics.
Modified Release Drug Products

Development of Modified Release Drug Products: Science-Led & Data-Driven Strategies
Site Spotlight

Spotlight on Reading, UK - Q&A with Chris Landeg, Site Head of Quotient Sciences Reading
HPAPI's

Understanding the Challenges of Working with Products containing High-Potency Active Pharmaceutical Ingredients (HPAPIs)
Formulation Development

How to Avoid Losing Time in Development when Bridging from First-in-Human Dosage Form to Robust and Scalable Phase II Drug Products

Share Your Development Challenge with our Scientists

Let's Talk

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.

Upcoming webinar

Orphan Drug Development For Rare Diseases

Tuft’s Center for the Study of Drug Development partners with Quotient Sciences for study on Translational Pharmaceutics.

Development of Modified Release Drug Products: Science-Led & Data-Driven Strategies

Spotlight on Reading, UK - Q&A with Chris Landeg, Site Head of Quotient Sciences Reading

Understanding the Challenges of Working with Products containing High-Potency Active Pharmaceutical Ingredients (HPAPIs)

How to Avoid Losing Time in Development when Bridging from First-in-Human Dosage Form to Robust and Scalable Phase II Drug Products

Share Your Development Challenge with our Scientists